Floatz logo

Olaparib

Advanced Solid Neoplasms

Merck Sharp & Dohme LLCSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Advanced Solid Neoplasms cohort.

Asset / SponsorPhaseRating
AGONISTIC ANTI-CD40 MONOCLONAL ANTIBODY ADC-1013
Janssen Research & Development, LLC
Phase 1CC
Tak-659
Calithera Biosciences, Inc
Phase 1D

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaDormant
BBB
Indicative ·
73 / 100
View asset →
fallopian tube serous adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →